Drug intelligence / Profile preview

KP301

Development stage: Preclinical
Lead developer: 科越医药

Overview

**KP301** is a preclinical biologic developed by Kira Pharmaceuticals (US), LLC, designed as a potent inhibitor of both the terminal complement pathway (TP) and alternative complement pathway (AP). It achieves fully reduced free C5 levels (<0.5 μg/mL), a key biomarker for TP inhibition, enabling sustained complement blockade for immune system diseases. Primarily targeted at autoimmune and inflammatory conditions involving excessive complement activation, such as neutrophilic and other autoimmune disorders.[3][4][11]

Targets

Beyond the preview

Go deeper on KP301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP301.

Explore the full profile